OTCM
CHGCF
Market cap66bUSD
, Last price
Name
Chugai Pharmaceutical Co Ltd
Chart & performance
P/E
—
P/S
—
EPS
263.74
Vol. 1Y
—
Shs. 5Y
0.01%
Rev. 5Y
9.84%
Div Yld LY
—
Div Yld TTM
—
Revenues
1.26t
+7.46%
Net income
434.01b
+12.06%
CFO
389.45b
-12.99%
Dividend
Jun 29, 20260.42016 /sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and Overseas businesses. The Domestic Business covers the manufacturing, research, and development operations in Japan. The Overseas business comprises of sales and production in Europe, Taiwan and China. The company was founded by Juzo Ueno on March 10, 1925 and is headquartered in Tokyo, Japan.
Key people
Osamu Okuda
President, Chief Executive Officer, Representative Director · since 2021
Shinji Hidaka
Senior Executive Officer · since 2024
Hitoshi Iikura
Senior Executive Officer, Chief Director of Translational Research, Director · since 2024
Shoko Kimijima
Senior Executive Officer · since 2025
Tsukasa Kusano
Senior Executive Officer, Manager of Project Life Cycle Management Unit · since 2024
Norihisa Onozawa
Senior Executive Officer, Director of Corporate Planning · since 2024
Kaori Ouchi
Senior Executive Officer · since 2024
Iwaaki Taniguchi
Senior Executive Officer, Chief Financial Officer, Director · since 2024
Yoshiyuki Yano
Senior Executive Officer · since 2023
Naoya Fujihara
Executive Officer · since 2024
Tomoyuki Igawa
Executive Officer, Chief Director of Research · since 2024
Shinya Takuma
Executive Officer, Chief Director of Production Technology · since 2022
Teresa Graham
Non-Executive Director · since 2023
Thomas Schinecker
Non-Executive Director · since 2023
Boris Zaitra
Non-Executive Director · since 2025
Mariko Momoi
Independent Director · since 2020
Fumio Tateishi
Independent Director · since 2023
Independent Director · since 2023
Headquarters & legal address
北区浮間５丁目５番１号
東京都, 13 115-0051
JP
東京都, 13 115-0051
JP
Other language
Chugai Pharmaceutical Co., Ltd.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||